(Q50302063)

2 March 2018

title

Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). (English)

1 reference

2 March 2018

1 reference

1 reference

Dipak P Shah

1

1 reference

2 March 2018

Jose L Baez-Escudero

2

1 reference

2 March 2018

Ian L Weisberg

3

1 reference

2 March 2018

John F Beshai

4

1 reference

2 March 2018

Martin C Burke

5

1 reference

2 March 2018

publication date

30 September 2010

1 reference

2 March 2018

Pacing and Clinical Electrophysiology

published in

1 reference

2 March 2018

volume

35

1 reference

2 March 2018

issue

3

1 reference

2 March 2018

page(s)

e62-4

1 reference

2 March 2018

Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8159.2010.02913.X

10.1111/J.1540-8159.2010.02913.X

21 January 2018

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018